Transcatheter aortic valve implantation (TAVI)

State of the art techniques and future perspectives

Enrico Ferrari, Ludwig Karl von Segesser

Department of Cardio-Vascular Surgery, University Hospital of Lausanne (CHUV), Lausanne, Switzerland

Correspondence to:
Dr. Enrico Ferrari
Department of Cardiovascular Surgery
Centre Hospitalier Universitaire Vaudois (CHUV)
46, rue du Bugnon
CH-1011 Lausanne
Switzerland
enricoferrari@bluewin.ch

Key words: aortic stenosis; transcatheter aortic valve implantation; transapical; transfemoral; valved stent; stent-valve

Introduction

Degenerative aortic valve stenosis (AS) occurs in the elderly and represents the most frequent acquired heart valve disease, with a prevalence of 4.6% in adults aged 75 years or more. Due to the ageing population in developed countries, the amount of elderly suffering from severe symptomatic AS is constantly increasing and cardiologists as well as cardiac surgeons worldwide are already facing a greater burden from this valvular disease [1–4].

Concerning the standard treatment for symptomatic AS, there is still a lack of pharmacological therapies to prevent or slow down the progression of this potentially life-threatening disease and, unfortunately, percutaneous aortic valve balloononing (valvuloplasty) has revealed questionable short-term and mid-term results [5, 6]. Thus, this technique is no longer considered a valid therapy for AS but is still indicated to temporarily improve the patient’s haemodynamic (in case of AS followed by acute cardiac decompensation), or as a palliative treatment for patients not referred to open heart surgery. As a consequence, for the last fifty years the standard open heart surgery for aortic valve replacement (AVR) with use of cardiopulmonary bypass (CPB), sternotomy (or mini-sternotomy), aortic cross clamping and cardioplectic arrest represents the treatment of choice and the standard of care for patients carrying severe AS with symptoms, and the mid- and long-term results are very satisfactory [7–10]. Moreover, during the last twenty years it has been proven that the refinement of surgical techniques, anaesthesiological management and intensive care treatments have favourably influenced the outcome and the surgical results of patients aged 80 years or more, who underwent isolated AVR [11–16].

However, there is still a pool of patients affected by severe AS requiring AVR (estimated at 33% of patients with severe symptomatic AS) who do not undergo valve surgery because they are considered too old (nonagenarians, centenarians) for such an invasive procedure, or because they are affected by concomitant co-morbidities that

Summary

Transcatheter aortic valve therapies are the newest established techniques for the treatment of high-risk patients affected by severe symptomatic aortic valve stenosis. The transapical approach requires a left anterolateral mini-thoracotomy, whereas the transfemoral method requires an adequate peripheral vascular access and can be performed fully percutaneously. Alternatively, the trans-subclavian access has been recently proposed as a third promising approach. Depending on the technique, the fine stent-valve positioning can be performed with or without contrast injections. The transapical echo-guided stent-valve implantation without angiography (the Lausanne technique) relies entirely on transoesophageal echocardiogramme imaging for the fine stent-valve positioning and it has been proved that this technique prevents the onset of postoperative contrast-related acute kidney failure. Recent published reports have shown good hospital outcomes and short-term results after transcatheter aortic valve implantation, but there are no proven advantages in using the transfemoral or the transapical technique. In particular, the transapical series have a higher mean logistic Euroscore of 27–35%, a procedural success rate above 95% and a mean 30-day mortality between 7.5 and 17.5%, whereas the transfemoral results show a lower logistic Euroscore of 23–25.5%, a procedural success rate above 90% and a 30-day mortality of 7–10.8%. Nevertheless, further clinical trials and long-term results are mandatory to confirm this positive trend. Future perspectives in transcatheter aortic valve therapies would be the development of intravascular devices for the ablation of the diseased valve leaflets and the launch of new stent-valves with improved haemodynamic, different sizes and smaller delivery systems.
noticeably increase the operative risk (too high risk for hospital mortality and/or onset of severe postoperative complications) [17]. The amount of people included in this subgroup will likely increase constantly during the upcoming decades because an ageing population will have more co-morbidities and, consequently, doctors and surgeons will deny high-risk AVR.

In this scenario, transcatheter minimal invasive beating heart aortic valve therapies (transcatheter aortic valve implantation: TAVI) have been considered as attractive alternatives to the standard AVR for patients carrying an elevated predictable operative risk or in case of peculiar clinical situations that could compromise the patient’s outcome after standard open heart surgery.

**Aortic stent-valves**

In the 1990s, the visionary idea of implanting valved stents in the aortic annulus stimulated basic research, computer simulations, bench tests and animal models all over Europe, and, at the beginning of this century (April 2002), the first transcatheter aortic stent-valve implantation in human (using an antegrade trans-septal venous approach through a femoral vein) was performed by Dr. Cribier in Rouen, France [18–26].

Since then, only two different sutureless transcatheter aortic stent-valves have been developed, tested and, subsequently, introduced into the current clinical practice. These two devices, which are routinely implanted in several highly specialised cardiac centres, are the CoreValve® system by Medtronic, Minneapolis, MN, (fig. 1), which is only available for a retrograde purpose, and the Edwards Sapien™ THV stent-valve system by Edwards Lifesciences INC, Irvine, CA, (fig. 2), which is available for both the antegrade and the retrograde applications. However, a few more devices, allowing for antegrade and/or retrograde implantations, have already passed the animal lab tests and are now under human clinical investigation (see the chapter: future perspectives).

**Medtronic CoreValve®**

The CoreValve® system (fig. 1) is a self-expandable nitinol stent with an inner porcine pericardial valve, which received the CE mark in 2007. The stent-valve is designed to sit into the aortic root and to anchor into the aortic annulus. However, the valve function is more supra-annular and a skirt of pericardium, bordering the lower portion of the stent-valve, prevents paravalvular leaks. The valve is available in two sizes, the 26 mm and the 29 mm, and the delivery system (only for retrograde applications) has an external diameter of 18F allowing for a transfemoral (TF) (recommended) or a trans-subclavian (off-label use) transcatheter stent-valve implantation.

**Edwards Sapien™ THV**

The Edwards Sapien™ THV stent-valve (fig. 2) is a tube-like stainless steel balloon-expandable stent, of 14–16 mm in length, with an inner bovine pericardial valve treated with the ThermaFix™ anticalcification system, that received the CE mark approval in October and December 2007 for its transfemoral and transapical (TA) applications, respectively. The stent-valve is inserted and deployed within the aortic annulus and sits in a sub-coronary position. The Sapien™ stent-valve is available in two sizes, a 23 mm (14 mm length) and a 26 mm (16 mm length), and can be introduced via a transapical (antegrade, Edwards Ascendra™ system) or a transfemoral (retrograde, Edwards RetroFlex™ system) transcatheter approach that requires a 22F (for the 23 mm) or a 24F (for the 26 mm) sheath.

**Edwards Sapien XT™ THV**

The new generation of Edwards Sapien™ THV, the XT generation (fig. 2), was officially launched in the second quarter of 2010. This new device, available for transapical and transfemoral applications, has important innovations: first of all, both the retrograde and the antegrade implantation will benefit from new smaller sheaths; an 18F sheath for transfemoral access (allowing for full percutaneous procedures) and a 22F or 24F sheath for the transapical access. The new transfemoral delivery system is called the NovaFlex™ system, whereas the new transapical delivery
system is named Ascendra II™ and both are easier to use compared to the older versions. Other important innovations are the new stent (cobalt-chromium) that allows for a smaller crimped profile with a higher resistance to mechanical stress, and the re-designed valve leaflets that gain a “semi-closed” profile at rest (instead of an open profile) allowing for an easier closure under pressure once implanted. Moreover, a new 29 mm Sapien XT™ THV for transapical applications only, will be available in 2011.

Implantation approaches

With regards to the delivery systems and their introduction into the ascending aorta, two specific pathways have been explored so far: the antegrade way employing direct transapical access, and the retrograde way that uses either transfemoral or, alternatively, trans-subclavian access [27–30].

The transapical approach (TA)
The main advantages of performing transapical procedures (fig. 3) are: i) the feasibility does not rely on the absence of a concomitant peripheral vascular disease or previous aortic surgery; ii) the delivery system seems to be more “steady” and the procedure itself more “straightforward”, and iii) this access potentially reduces the risk of calcium dislodgment due to the passage of a stiff transfemoral device into a diseased aortic arch. A transapical transcatheter aortic valve implantation (TA-TAVI) can be performed in the operating room, in a hybrid room, or in a catheterisation laboratory with patients under general anaesthesia (high epidural anaesthesia in a conscious patient has also been reported). Regardless to the place where the TA is performed, it is a prerequisite that high-quality fluoroscopic imaging must be guaranteed. Apical bleeding is very rare, mostly related to patients’ tissue fragility and/or to the team learning curve, and represents the most dangerous complication related to the transapical access itself. Once occurred, CPB resuscitation can be helpful in order to safely repair the tear [31]. In transapical TAVI, the cardiac apex is prepared through a small left anterolateral minithoracotomy using a purse-string or a crossing suture reinforced by pledgets and, after the procedure, a chest tube is routinely inserted into the left pleura with pain releasers injected in the intercostal tissue.

The transfemoral approach (TF)
The transfemoral procedure (fig. 4) for transcatheter aortic valve implantation (TF-TAVI) is mostly performed in the cardiac catheterisation laboratory or in the hybrid room and one of the main advantages of this technique is that it allows fully percutaneous implantations in conscious patients, as long as the peripheral vessels have an adequate caliber (more than 6 mm diameter), there are no very tortuous vessels, and vascular closure devices are available. Alternatively, the standard technique requires surgical preparation of the common femoral artery (rarely, the iliac artery).
under local or general anaesthesia. According to the latest international guidelines, the presence of peripheral vascular disease, small vessel diameters, tortuous vessels, aortic disease or previous aortic surgery contraindicates this approach. Major and minor postoperative vascular complications have been reported quite often in recent series (up to 40% of incidence) and some critical events (vessels dissections, ruptures or avulsions) might be catastrophic when not promptly and adequately treated.

The trans-subclavian approach

Trans-subclavian access is an alternative retrograde pathway that has been recently explored. It requires a surgical exposure of the left subclavian artery and an adequate minimal vessel inner diameter for 18F delivery systems (6 mm diameter). There are some advantages in using this approach: first of all, the distance between the site of introduction and the aortic valve is short, compared to the transfemoral option, and it results in a steadier pathway. Secondly, as long as the subclavian artery is intact, the trans-subclavian procedure can be performed in case of a concomitant vascular disease involving the abdominal aorta or the legs and does not require a thoracotomy. Unfortunately, the presence of a patent internal mammary artery, such as a diseased subclavian artery, in redo coronary surgery contraindicates this approach. However, at the moment this interesting approach remains “off-label” and is not yet formally recommended by the industry.

The trans-aortic approach

In case of severe peripheral vascular disease and a concomitant contraindication to transapical procedures (i.e. an apical thrombus), an alternative, interesting, retrograde approach has been proposed: through an upper “J-shape” mini-sternotomy, the guidewires and the delivery system are inserted, retrogradely, into the ascending aorta and are secured with a double purse-string suture (4-0 polypropylene). Then, the TAVI is performed as a transfemoral procedure. The presence of “porcelain” aorta and the risk of postoperative massive bleeding limit this approach to selected cases.

Patient selection and inclusion criteria

First of all, we have to state that patients suitable for TAVI have to be selected by a multidisciplinary group of experts composed of cardiologists and cardiac surgeons, and the entire process requires a team approach involving an anaesthesiologist and doctors from the intensive care unit. The patients’ enrolment follows the latest international guidelines for TAVI [28]. Briefly, elderly patients with severe symptomatic AS and a very high predictable operative risk (defined as a Logistic Euroscore-above 20% or an STS score above 10%) are good candidates for a transcatheter therapeutic option. However, all cardiac centres performing TAVI have already experienced the screening of special candidates who carry a “clinically estimated” surgical risk too high for standard AVR, despite the Logistic Euroscore or the STS score lying below the above mentioned limits. In particular, a heavily calcified ascending aorta (“porcelain” aorta), the presence of a severe congenital thoracic distortion, a severe liver disease (i.e. a liver cirrhosis with a CHILD classification A or B), the presence of non-cardiac tumours with a good mid-term prognosis or a pre-dialysis renal insufficiency, have always been considered important risk factors contraindicating standard AVRs with CPB. Generally speaking, we can state that all contraindications to CPB use, sternotomy, cardiopulmonary cardiac arrest or aortic cross-clamping are good indications for a TAVI.

The native aortic annulus diameter also plays a key role: a valve annulus measuring 19 to 25 mm diameter is recommended for a 23 mm or a 26 mm Sapien™ THV, whereas an aortic annulus measuring 20 to 27 mm requires a CoreValve®. Smaller and bigger valve diameters are not suitable, at the moment, for transcatheter valve therapies despite the fact that, as soon as the 29 mm Sapien XT™ THV will be available, a wide 28 mm aortic annulus will also become treatable.

A recent myocardial infarction (less than 3 months), an extremely severe pulmonary dysfunction (avoiding thoracotomy and intubations), and the presence of an apical thrombus are considered formal contraindications for transapical TAVI, whereas a left ventricular ejection fraction (LVEF) below or equal to 20% contraindicates all TAVI procedures.

A congenitally bicuspid aortic valve is also included in the contraindication list for TAVI, however, a successful case of TAVI in a congenital aortic bicuspidy has recently been published [32].

All major peripheral vascular problems involving the aorta or the ilio-femoral arteries contraindicate transfemoral approaches for TAVI, but even a standard transapical TAVI normally requires, at least, one valid peripheral arterial access for the introduction of an arterial catheter (a “pigtail” catheter) to inject contrast medium into the ascending aorta. However, we were able to demonstrate that a transapical TAVI can also be successfully performed in the absence of any valid arterial access, when the intraoperative angiographies are avoided and the stent-valve is positioned solely under transeosophageal echo-guidance (see Figure 5).
the chapter: echo-guided transapical TAVI without angiography) [33].

With regard to redo aortic valve surgery, in a few experienced cardiac centres it has recently become routine to perform “valve-in-valve” (VinV) procedures in case of degenerated aortic bio-prostheses (B) high-risk patients. In fact, the VinV strategy was developed to avoid high-risk redo cardiac surgery in old patients with degenerated valves, and is based on the implantation of a sized stent-valve into the stented or stentless diseased bio-prosthesis (the recommended minimal bio-prosthesis diameter for the transapical implantation of an Edwards Sapien™ stent-valve is 23 mm), and the latest postoperative clinical results are satisfactory [34, 35] (fig. 5). However the transcatheter VinV remains “off-label” and further clinical investigations are recommended.

Another new approach involving transcatheter procedures in case of a failed mitral valve repair is the “valve-in-a-ring” (VinR) procedure that has been very recently proposed (no clinical cases have been published yet and a case report is under review to the Editor of the European Journal of Cardio-Thoracic Surgery). The procedure is based on the implantation, retrogradely, via a transapical approach, of a stent-valve into a failed mitral repair with a ring. However this approach is under evaluation, is an “off-label” use and more studies are necessary to establish its feasibility with different rings (flexible, rigid, semi-rigid) and different sizes.

Preoperative assessment

Patients enrolled for TAVI undergo preoperative clinical and radiological investigations in order to evaluate their general clinical state, the size of the aortic annulus, the presence of concomitant vascular disease and the presence of coronary disease [36].

The standard protocol for TAVI includes the following tests:
- thorax X-ray
- transthoracic echocardiogramme (first level of screening)
- peripheral vascular Doppler (first level of investigation)
- transoesophageal echocardiogramme (second level)
- heart catheterisation with coronary angiogramme, aortography and, eventually, peripheral injections.
- cardiac and vascular computed-tomography scan followed by 3-dimentional reconstructions of the heart, the aorta, the iliac, the femoral and, eventually, the subclavian artery to enable measurements to be done.

Surgical techniques

Aortic stent-valve implantation with angiography

The transapical TAVI (TA-TAVI) (fig. 3) requires a left anterolateral mini-thoracotomy through the 5th or the 6th intercostal space. In this phase, a transthoracic echocardiogramme is useful to identify the cardiac apex, in order to place a mark on the skin. Once the pleura is opened, it is also useful to insert a finger through it in order to identify the apex position: if the apex is easily accessible, the procedure can be performed through this access, otherwise the upper or the lower intercostal space can be taken into consideration. After opening the pericardium, typically two concentric purse string sutures (2-0 or 3-0 polypropylene sutures with 1×0.5 cm large Teflon pledgets) have to be prepared on the left lateral wall of the cardiac apex. Care has to be taken in order to insert the needle through the muscle and not through the fat in order to avoid life threatening bleedings from ventricular tears. Once the guidewires are passed through the apex and across the aortic valve, it is important to advance them into the descending aorta using a standard pigtail catheter. Following this, the authors immediately insert the bigger sheet (30F) which is used to introduce the delivery system for the Edwards Sapien™ THV. Through this big sheet, we first perform the aortic valvuloplasty and then we perform the stent-valve implantation, both under rapid pacing (heart beat rate >180 bpm). In case of a VinV procedure, we do not perform the
valvuloplasty in order to avoid the dislodgments of valve material.

In order to avoid parallax phenomena between the aorta and the stent-valve during the procedure, the fluoroscopy unit has to be precisely orientated: repeated angiographies are performed before the balloon valvuloplasty and the three leaflets of the aortic valve have to lie on one single line (fig. 6A). The stent-valve positioning requires angiographies to verify the placement of the cramped stent-valve is in the ideal landing zone (the stent-valve has to lie 40% on the aortic side and 60% on the ventricular side), and, at the end of the procedure when the valve is in place, a postoperative angiographic control is also routinely performed to verify the coronary patency and the absence of major paravalvular leaks (fig. 6B). The intraoperative TEE is used to confirm the valve positioning, the absence of major (>2+) paravalvular leaks as well as to verify the leaflets’ motion and integrity.

The transfemoral TAVI (TF-TAVI) (fig. 4) requires valid femoral access or, rarely, iliac access (where an 8 mm diameter vascular graft is anastomosed to the vessel). The TF procedure requires the surgical preparation of the femoral vessel or, since the advent of small 18F delivery systems, it can be performed fully percutaneously. Once inserted into the aorta, the guidewires are advanced and placed across the aortic arch and through the stenosed aortic valve. During this retrograde pathway it is important to prevent calcium dislodgment from a diseased aortic wall. The positioning of the fluoroscopy unit follows the same rules already described for the TA procedure and repeated angiographies are performed. Once the valvuloplasty is performed and the cramped stent-valve is inserted across the native valve, an aortography is performed to confirm the positioning. In the case of a conscious patient, the postoperative TEE control is replaced by TTE and angiography.

The two different stented valves which are available are deployed in two different ways: under rapid cardiac pacing (heart beat rate >180 bpm) the Sapien™ THV is expanded using the rapid inflation of the inner catheter-balloon, whereas the CoreValve® auto-expands after the removal of the delivery system. Once the valve is in place, the delivery system is removed and a closure system is employed in case of a percutaneous access.

Despite disadvantages, intraoperative cardiac imaging is crucial for a successful stent-valve implantation. A major disadvantage, related to the use of high doses of contrast medium for the angiographies, is the quite relevant incidence of contrast-related postoperative acute renal failure after TAVI (up to 33%), which represents an important complication negatively affecting the patients’ outcome [37, 38].

Echo-guided transapical TAVI without angiography
Routine echo-guided transapical TAVI without angiography was proposed by our group in 2009 to prevent contrast-related acute postoperative renal failure [39–41], and is based on our wide experience (more than 500 procedures performed) on endovascular aorta repair (EVAR) without angiography [42].

The technique does not differ from standard transapical TAVI as far as the surgical details are concerned. However, preoperative and the intraoperative cardiac imaging are peculiar and technical details have already been described in a previous report [41]. The essential steps can be briefly summarised as follows: an injected (very low dose) cardiac computer tomography (CT-scan) is performed preoperatively to measure the annulus diameter and the distance with the coronary ostia, and to analyse the aortic root (3-D reconstructions). Two angles are identified, a left-lateral and a cranial one, indicating the orientation of the aortic valve plane in the space (fig. 7). Using these angles the fluoroscopy is orientated into its final position, and the use of repeated aortographies is no longer necessary (fig. 8). The valve positioning is the crucial phase and is based on high-quality TEE images acquired by experienced specialists [43] (fig. 9). The fluoroscopy without contrast still plays a key-role for the placement of guidewires and catheters, and for the valve ballooning and the stent-valve balloon inflation. At the end of the procedure, the haemodynamic control is assessed by TEE imaging and measurements and if the patient is stable the coronary angiogramme and the aortography are no longer performed.

Clinical results
Published results have shown satisfactory short-term outcomes after transapical and transfemoral TAVI but, to the best of our knowledge, there is not yet evidence that a superiority exists between the two techniques. Thus, it would be of great interest to develop a three-arm, randomised, prospective clinical trial that statistically compares the standard AVR with the transapical and the transfemoral TAVI.

This interesting trial has not yet been developed but, during the last four years, some articles reporting cohorts of TAVI patients treated in Europe and Canada have been published and the main contents are summarised in table 1 [44–52].

What is clear and evident is that the two populations of TF and TA patients are not comparable. In fact, the logistic Euroscore is usually 1/3 higher in the TA groups according to the fact that these groups suffer from a higher incidence of vascular disease. Concerning hospital mortality (30 days), the results show that the TA groups have a higher operative mortality compared to the TF groups, whereas the TF groups have more incidence of postoperative stroke. Another clear finding is that the TF procedures performed using the Core Valve® system have a higher incidence of pace maker implantation.

As an example of a transcatheter platform, we can share our clinical experience: we started in 2002 with animal experiments [19, 20, 22–24], and we continued in 2006 with the first transapical stented valve (ATS 3F) implanted into a human in Switzerland (fig. 10).

With regards to the Edwards SapienTM THV, we launched TA implants very early in 2008 and, during a period of 18 months, 40 transapical TAVI and 2 transfemoral cases (TF is still performed under proctor supervision) were performed. The mean age of the population was 81 ± 8 years, the mean logistic Euroscore was 35 ± 14.5% (range 14–75%), and there were 24 females (60%). Special indications included: previous thoracic radiotherapy (2 patients), porcelain aorta (3) and liver cirrhosis with oesophageal varices (CHILD B classification) in 2 patients. We also performed two ViVi procedures: a 23 mm SapienTM in 2 degenerated 23 mm bio-prosthesis (a 7 year old Mitroflow and a 7 year old Edwards Perimount). Three patients were in a critical preoperative state, three had chronic renal failure with a pre-dialysis state (blood creatinine level chronically above 230, 250 and 300 µg/dl, respectively), 15 (37.5%) had chronic pulmonary disease (COPD), 30 (75%) had a peripheral vascular disease (6 patients underwent previous vascular surgery), 21 (52.5%) suffered from coronary disease (7 patients had previous surgery and 4 had coronary angioplasty/stenting), and 15 suffered from chronic renal insufficiency (the mean preoperative blood creatinine and urea levels were 108 ± 70 µg/dl and 9.2 ± 5.6 mmol/l, respectively). The mean ejection fraction was 53 ± 12%. The procedural success rate was 97.5% and we implanted a 26 mm SapienTM THV 23 times and a 23 mm SapienTM THV 17 times. The 30-day mortality was 7.5% (3 patients died from severe right ventricular dysfunction, intra-procedural left-ventricular free wall rupture and late bilateral pneumonia) and we did not have patients with postoperative myocardial infarction, acute renal failure (the total mean postoperative blood creatinine and urea levels were 91.7 ± 60 µg/dl and 7.8 ± 3.6 mmol/l, respectively), and atrio-ventricular block. The post-procedural stroke rate was 0% but, unfortunately, a left hemiplegia occurred in an old lady at postoperative day 9, despite a therapy with aspirin (100 mg) and warfarin. The mean operative time was 108 ± 34 minutes and the postoperative recovery required a mean intensive care unit stay of 2.2 ± 3.5 days (median: 1 day) and a mean hospital stay of 15 ± 9 days (median: 12.5 days). A total of 34 patients were rapidly extubated and, among them, 8 patients were extubated in the operating theatre. The postoperative haemodynamic showed a mean trans-valvular gradient of 15 ± 9 (max) and 8.7 ± 5 mm Hg (mean), with 7 patients carrying a trivial (1+/4) paravalvular leak and 3 patients a mild (2+/4) paravalvular leak.

To summarise, our pioneering experience on TAVI is in line with the most-recent reports present in the literature (see the comparison in table 1). In particular, all centres who are familiar with this minimally invasive technique report a mean logistic Euroscore ranging between 27 and
35%, a procedural success rate mostly above 95% and a mean 30-day mortality rate between 7.5 and 17.5%. If the percutaneous transfemoral TAVI (with the two systems available at the moment) is taken into consideration, the published results show a lower mean logistic Euroscore ranging between 23 and 25.5%, a procedural success rate always above 90%, and a 30-day mortality rate around 7–10.8% [43–51].

It is remarkable that both the transapical and the transfemoral TAVI have a physiological learning curve and, in some recently published reports, the cohorts of patients are split into two groups: an earlier group (20–25 patients) that includes the learning curve phase, and a group of patients operated on more recently [46, 48]. In these papers, authors have concluded that the inclusion criteria did not change over the time and the mean logistic Euroscore remained unchanged or even increased in the most recent series, whereas the procedural successful rate, together with the 30-day mortality rate, ameliorated sensibly after the learning curve period. In our experience, we can confirm this downward trend for hospital mortality after the physiological learning curve phase, and we can also confirm that the surgical risk is higher in patients that were addressed most recently to transapical TAVI: in the first 20 cases performed in our centre, we had an observed 30-day mortality of 10% with a predicted operative mortality of 29% (by logistic Euroscore), whereas, within the second 20 cases performed, we had an amelioration in the observed 30-day mortality (5%) despite a worst predicted surgical risk of 40% (by log. Euroscore).

Nevertheless, more single- and multicentre reports with longer follow-ups are required to confirm the good trend of this promising transcatheter valve technology.

### Future perspectives

After the CE-mark approval, the transapical and the transfemoral TAVI performed with the Sapien™ THV and the CoreValve™ have become routine procedures in selected cardiac centres, allowing further hospitals to begin their own transcatheter valve programme soon. Therefore, we

---

**Table 1**

Comparison between the most recently published series of transapical and transfemoral transcatheter aortic valve implantations using the Edwards Sapien™ THV and the Medtronic CoreValve®.

<table>
<thead>
<tr>
<th>Study/Author</th>
<th>Patients (n)</th>
<th>Mean age (Y)</th>
<th>logistic ES (%)</th>
<th>STS score (%)</th>
<th>Success (%)</th>
<th>30-day mortality (%)</th>
<th>PM implantation (%)</th>
<th>Stroke rate (%)</th>
<th>Postop. renal failure (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Edwards Sapien™: transapical</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ferrari (Lausanne, Switzerland)</td>
<td>40</td>
<td>81</td>
<td>35</td>
<td>–</td>
<td>97.5</td>
<td>7.5</td>
<td>0</td>
<td>2.5</td>
<td>0</td>
</tr>
<tr>
<td>Ye (Vancouver, Canada) [44]</td>
<td>71</td>
<td>80</td>
<td>34.5</td>
<td>12.1</td>
<td>95.8</td>
<td>16.9</td>
<td>8.5</td>
<td>1.4</td>
<td>data not available</td>
</tr>
<tr>
<td>Rodés-Cabau (multicentric, Canada) [45]</td>
<td>177</td>
<td>80</td>
<td>–</td>
<td>10.5</td>
<td>96.1</td>
<td>11.3</td>
<td>6.2</td>
<td>1.7</td>
<td>haemodialysis: 3.4</td>
</tr>
<tr>
<td>Waller (multicentric, Germany) [46]</td>
<td>59</td>
<td>81</td>
<td>27</td>
<td>–</td>
<td>90</td>
<td>13.6</td>
<td>data not available</td>
<td>3.4</td>
<td>haemodialysis: 13.5</td>
</tr>
<tr>
<td>Wendt (Essen, Germany) [47]</td>
<td>40</td>
<td>82</td>
<td>41.6</td>
<td>16.5</td>
<td>97.5</td>
<td>17.5</td>
<td>data not available</td>
<td>0</td>
<td>12.5</td>
</tr>
<tr>
<td>Himbert (Paris, France) [48]</td>
<td>24</td>
<td>82</td>
<td>28</td>
<td>18</td>
<td>100</td>
<td>16</td>
<td>4</td>
<td>0</td>
<td>data not available</td>
</tr>
<tr>
<td>mean</td>
<td>81.00</td>
<td>33.22</td>
<td>14.28</td>
<td>96.15</td>
<td>13.80</td>
<td>4.68</td>
<td>1.50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Edwards Sapien™: transfemoral</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rodés-Cabau (multicentric, Canada) [45]</td>
<td>162</td>
<td>83</td>
<td>–</td>
<td>9</td>
<td>90.5</td>
<td>9.5</td>
<td>3.6</td>
<td>3</td>
<td>haemodialysis: 1.8</td>
</tr>
<tr>
<td>Himbert (Paris, France) [48]</td>
<td>51</td>
<td>82</td>
<td>25</td>
<td>15</td>
<td>90</td>
<td>8</td>
<td>6</td>
<td>6</td>
<td>data not available</td>
</tr>
<tr>
<td>Webb (Vancouver, Canada) [49]</td>
<td>113</td>
<td>85</td>
<td>25</td>
<td>8.7</td>
<td>94</td>
<td>8</td>
<td>4.4</td>
<td>5</td>
<td>4.4</td>
</tr>
<tr>
<td>mean</td>
<td>83.33</td>
<td>25.00</td>
<td>10.90</td>
<td>91.50</td>
<td>8.50</td>
<td>4.67</td>
<td>4.67</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CoreValve® 18F: transfemoral</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grube (Siegburg, Germany) [50]</td>
<td>102</td>
<td>82</td>
<td>24.5</td>
<td>8.6</td>
<td>91.2</td>
<td>10.8</td>
<td>33.3</td>
<td>2.9</td>
<td>data not available</td>
</tr>
<tr>
<td>Tamburino (Catania, Italy) [51]</td>
<td>30</td>
<td>82</td>
<td>25.3</td>
<td>–</td>
<td>97</td>
<td>6.7</td>
<td>20</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Piazza (multicentric) [52]</td>
<td>646</td>
<td>81</td>
<td>23</td>
<td>–</td>
<td>97.2</td>
<td>8</td>
<td>9.3</td>
<td>1.9</td>
<td>data not available</td>
</tr>
<tr>
<td>mean</td>
<td>81.67</td>
<td>24.27</td>
<td>8.60</td>
<td>95.13</td>
<td>8.50</td>
<td>20.87</td>
<td>2.60</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Procedural success: at least one stent-valve in place, no need for full sternotomy and patient leaving alive the OR/hybrid room/cath. lab.

Data not available: the variable does not appear in the manuscript, but it does not mean that the event did not happen.

ES: Euroscore.
will probably face a constant increase in stent-valve implantations with great benefits in terms of wider clinical trials and new technical/research investments.

Concerning the surgical indications, the high-risk elderly patient with severe and symptomatic AS will remain the ideal candidate for a while. However, as soon as the overall quality and longevity of these stent-valves has been proven by long-term follow-ups, patients carrying a lower predictable operative risk profile might be considered as candidates for TAVI. With regards to the technical developments, new futuristic tools that offer the opportunity to completely ablate, percutaneously, the diseased aortic valve leaflets before the stent-valve implantation are under development but, to the best of our knowledge, only few bench tests have been performed so far [53–56]. The stent-valve evolution will also provide new stent-valves for transapical and transfemoral applications, such as the Symetis stent-valve (Symetis SA, Lausanne, Switzerland) (fig. 11), and the Ventor Embracer™ stent-valve (Medtronic, Minneapolis, MN) for an exclusive transapical use, or the JenaClip™ stent-valve (JenaValve Technology, Munich, Germany) for both transapical and transfemoral applications [57, 58]. These new stented valves will bring innovations such as a greater variety of sizes, expected durability (due to the employed biological tissues and their treatment), simplicity in use (in particular for the valve positioning and implantation, and for the delivery system), and some interesting characteristics such as the self-orientation (the stent-valve leaflets will fit within the native aortic valve leaflets) and the self-expandability without need for rapid cardiac pacing.

Another evolution plan is the required vessel caliber for peripheral applications. In fact, the minimal vessel diameter required for the delivery system insertion during transfemoral and trans-subclavian TAVI procedures will continue to decrease as long as smaller delivery systems and smaller cramped stent-valves are developed by the industry. However, the extreme downsizing of the cramped stent-valve can compromise the quality of the metallic stent (which is cramped under high compressive forces) and the integrity of the leaflets (the thickness of the tissue employed to create valve leaflets is artificially lowered to minimise the size of the cramped valve).

Regarding the transapical minimal invasiveness and the latest alternative access point, our group has already proposed, in an animal model, the use of “natural orifices”, such as the umbilicus, for transapical or transventricular stent-valve implantations, where the delivery system is introduced into the human body through a natural skin access point [59].

More realistically, the fully percutaneous transfemoral stent-valve implantation already exists thanks to the downsizing of the delivery system and the flexibility of the cramped stent-valve. However, a future perspective would be the transapical TAVI performed under thoracoscopy, and the development of new ventricular closure devices appears to be the most important step for a fully percutaneous transapical procedure [60].

Conclusion

Transapical and transfemoral TAVI are the most recent established techniques for the treatment of isolated high-risk AS in the elderly and the latest publications have shown satisfactory hospital outcomes and mid-term results (up to two years). As a consequence, it can be presumed that the indications for this disruptive procedure will expand towards younger and less risky candidates as soon as ongoing clinical trials provide supporting long-term results.

In the near future, the evolving technology will provide new stent-valves with ameliorated designs and performance, and new smaller delivery systems allowing for less invasive procedures and a lower risk of vascular and cardiac injuries.

It should not be forgotten that the cooperation between cardiac surgeons, cardiologists, anaesthesiologists, radiologists and technicians (the so-called teamwork or team approach) is one of the most important parts of the entire TAVI process and its focus is the patient’s physical and mental wellness. In conclusion, to continue to guarantee the extraordinary and, maybe, unexpected success of this new minimally invasive procedure, the team approach should remain a key-point for all teams who intend to create a new TAVI platform soon.

Funding / potential competing interests

No funding; no competing interests.

References

Society for Cardiovascular Angiography and Interventions and the So-


12 Asimakopulos G, Edwards MB, Taylor KM. Aortic valve replacement in patients 80 years of age and older: survival and cause of death based on
1100 cases: collective results from the UK valve registry. Circula-

13 Sundt TM, Bailey MS, Moon MR, Mendeoloff EN, Huddleston CB, Pasque MK, Barker HB, Gay WA Jr. Quality of life after aortic valve replacement

14 Chukuwemeka A, Borger MA, Ivanov J, Armstrong S, Feindel CM, David TE. Valve surgery in octogenarians: a safe option with good

valve implantation in octogenarians: risk factors for early and late mor-

16 Kolli P, Kerzmann A, Honore C, Cornette L, Limet R. Aortic valve sur-
ery in octogenarians: predictive factors for operative and long-term

making in elderly patients with severe aortic stenosis: why are so many

18 Cribier A, Eltchaninoff H, Bash A, Borenstein N, Tron C, Bauer F, Derumeaux G, Anselme F, Laborde F, Leon MB. Percutaneous trans-
catheter implantation of an aortic valve prosthesis for calcific aortic

19 Zhou JQ, Corso AF, Huber CH, Tozzi P, von Segesser LK. Self-expand-
able valved stent of large size: off-bypass implantation in pulmonary

20 Ma L, Tozzi P, Huber CH, Taud S, Gerele G, von Segesser LK. Double-
crowned valve stents for off-pump mitral valve replacement. Euro J

21 Anderson HR, Knadsen LL, Hasenkam JM. Transluminal implantation of
total artifical valves. Description of a new expandable aortic
valve and initial results with implantation by catheter technique in

22 Corso AF, Zhou J, Tozzi P, von Segesser LK. Off-bypass implantation
of a self-expandable valved stent between inferior vena cava and right

23 Huber CH, Marty B, von Segesser LK. Acceptance and introduction of
disruptive technologies – simple steps to build a fully functional pul-

24 Huber CH, Tozzi P, Corso AF, Marty B, Ruchat P, Gersbach P, Nas-
ratulla M, von Segesser LK. Do valved stents compromise coronary

25 Boudjemline Y, Bonhoeffer P. Steps toward percutaneous aortic

heart valves: from animal experimentation to the first human implant-

27 Walther T, Dewey T, Borger MA, Kempejt F, Linke A, Becht R, Falk
V, Schuler G, Mohr FW, Mack M. Transapical aortic valve implanta-

28 Vahanian A, Alfieri OR, Al-Attar N, Attinues MJ, Bax J, Cormier B, et al. Transcatheater valve implantation for patients with aortic sten-
osis: a position statement from the European Association of Cardio-
Thoracic Surgery (EACTS) and the European Society of Cardiology (ESC), in collaboration with the European Association of Percutaneous

29 Cribier A, Litzyer PY, Eltchaninoff H, Godin M, Tron C, Bauer F, Bessou JP. Technique of transcatheter aortic valve implantation with
the Edwards-Sapien heart valve using the transfemoral approach. Herz.

transapical approach for aortic valve implantation. J Thorac Cardio-

31 Al-Attar N, Ghabbane W, Himbert D, Rau C, Raiffoud R, Messika-
Zeitoun D, Brochet E, Vahanian A, Natal P. Unexpected complications
88:90–4.

LK. Successful transapical aortic valve implantation in a congenital

33 Ferrari E, Marucci C, Sulzer C, von Segesser LK. Which available
transapical transcatheter valve fits into degenerated aortic biopros-

JG. CT of the ilio-femoral arteries using direct aortic contrast injection:
proof of feasibility in patients screened towards percutaneous aortic

35 Strauch JT, Scherner MP, Haldenwang PL, Pfister R, Kubo EW, Mader-
shallian N, et al. Minimally invasive transapical aortic valve implanta-
89:465–70.

36 Aregger F, Wenausser P, Hellige GK, Kladner A, Carrel T, Windekir
S, Frey FJ. Risk of acute kidney injury in patients with severe aortic
valve stenosis undergoing transcatheter valve replacement. Nephrol Di-

37 Ferrari E, Sulzer C, Rizzo E, von Segesser LK. A fully echo-guided

38 Ferrari E, Marucci C, Di Bernardo S, von Segesser LK. Feasibility of
transapical aortic valve implantation guided by intracardiac ultrasound

39 Ferrari E, Sulzer C, Marucci C, Rizzo E, Tozzi P, von Segesser LK.
Transapical aortic valve implantation without angiography – proof of

40 von Segesser LK, Marty B, Ruchat P, Bogen M, Gallino A. Routine use
of intravascular ultrasound for endovascular aenurem repair: an-
giography is not necessary. Eur J Vase Endovasc Surg. 2002;23:537–42.

41 Moss RR, Irves E, Pasupati S, Humphries K, Thompson CR, Munt B,
Sinhal A, Webb JG. Role of echocardiography in percutaneous aortic

42 Ye J, Cheung A, Lichtenstein SV, Nielispfach F, Albugami S, Masson
JG. Transapical transcatheter aortic valve implantation: follow-up to 3

al. Transcatheater aortic valve implantation for the treatment of severe
symptomatic aortic stenosis in patients at very high or prohibitive
surgical risk: acute and late outcomes of the multcenter Canadian experi-

MT, et al. Transapical minimally invasive aortic valve implantation:

45 Wendt D, Eggbebrecht H, Kahler P, Heine T, Kottenberg E, Massoudy
P, et al. Experience and learning curve with transapical aortic valve im-

46 Himbert D, Descoutures F, Al-Attar N, Jung B, Ducroz G, Déniault
T, et al. Results of transfemoral or transapical aortic valve implantation
following a uniform assessment in high-risk patients with aortic stenos-


